Team Member

Antje is an accomplished leader in translational drug development, renowned for her ability to move innovative therapies from concept to clinic. Over the past two decades, she has played a pivotal role in advancing more than 20 drug candidates—including protein therapeutics and small molecules—across oncology, inflammation, and metabolic diseases.

Her core expertise spans translational PK/PD modeling, clinical pharmacology, and translational science with a special focus on precision dosing and dose optimization to improve patient outcomes. Antje has held senior roles in biotech, mid-size, and large pharmaceutical companies, including Roche, 3T Biosciences, Altana Pharma and Pieris Proteolab.

In August 2024, Antje founded tkc suisse where she provides consultancy services to biotech companies, focusing on predictive approaches that bridge the gap from bench to bedside. Together with other subject matter experts, she develops clinical decision support tools designed to assist doctors in tailoring drug dosing for individual patients. By leveraging advanced simulation techniques, these tools enable healthcare professionals to optimize treatment strategies and improve patient outcomes.